Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 19/20 | 0.59 |
| ▸ | OXTR | P30559 | 13/20 | 0.59 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.59 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18917292 | 0.85 | AVPR1A (0.65) | AVPR1AOXTRAVPR2TSPOCHRM2 | |
| SCHEMBL4832029 | 0.83 | AVPR1A (0.60) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL4831821 | 0.83 | AVPR1A (0.68) | AVPR1AOXTRAVPR2TSPOCHRM2 | |
| SCHEMBL18917272 | 0.81 | AVPR1A (0.70) | AVPR1AOXTRAVPR2TSPOCHRM2 | |
| SCHEMBL26185549 | 0.81 | AVPR1A (0.75) | AVPR1AOXTRAVPR2TSPOCHRM2 | |
| SCHEMBL30046134 | 0.81 | AVPR1A (0.75) | AVPR1AOXTRAVPR2TSPOCHRM2 | |
| SCHEMBL26185552 | 0.79 | AVPR1A (0.67) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL30046935 | 0.79 | AVPR1A (0.67) | AVPR1AOXTRAVPR2TSPO | |
| SCHEMBL6024708 | 0.79 | AVPR1A (0.62) | AVPR1AOXTRAVPR2TSPOCHRM2 | |
| SCHEMBL20277568 | 0.78 | HTT (0.61) | AVPR1AOXTRAVPR2TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2006-07-27 | — | — | US | disclosed |
| EP-1592693-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | Ferring B.V. (NL) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| EP-1449844-A1 | benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2004-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885OXTR 4/4885AVPR2 2/4885 |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885OXTR 4/4885AVPR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.